Globus Medical Inc (GMED) Holdings Decreased by OxFORD Asset Management LLP

OxFORD Asset Management LLP reduced its position in Globus Medical Inc (NYSE:GMED) by 46.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 81,729 shares of the medical device company’s stock after selling 71,657 shares during the quarter. OxFORD Asset Management LLP owned about 0.08% of Globus Medical worth $2,430,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Globus Medical by 0.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,538 shares of the medical device company’s stock valued at $349,000 after purchasing an additional 31 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Globus Medical by 1.2% during the second quarter. PNC Financial Services Group Inc. now owns 3,036 shares of the medical device company’s stock valued at $100,000 after acquiring an additional 35 shares in the last quarter. Alps Advisors Inc. grew its stake in shares of Globus Medical by 0.3% during the second quarter. Alps Advisors Inc. now owns 17,464 shares of the medical device company’s stock valued at $579,000 after acquiring an additional 45 shares in the last quarter. Advisor Group Inc. grew its stake in shares of Globus Medical by 2.0% during the second quarter. Advisor Group Inc. now owns 3,434 shares of the medical device company’s stock valued at $114,000 after acquiring an additional 68 shares in the last quarter. Finally, 1st Global Advisors Inc. grew its stake in shares of Globus Medical by 1.2% during the second quarter. 1st Global Advisors Inc. now owns 11,308 shares of the medical device company’s stock valued at $375,000 after acquiring an additional 130 shares in the last quarter. 72.20% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider A Brett Murphy sold 51,449 shares of Globus Medical stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $35.00, for a total transaction of $1,800,715.00. Following the sale, the insider now owns 49,768 shares of the company’s stock, valued at $1,741,880. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David D. Davidar sold 55,383 shares of Globus Medical stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $40.66, for a total value of $2,251,872.78. Following the sale, the director now directly owns 752,236 shares in the company, valued at approximately $30,585,915.76. The disclosure for this sale can be found here. Insiders own 28.21% of the company’s stock.

GMED has been the subject of several recent analyst reports. BidaskClub downgraded Globus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 26th. Barclays lowered their target price on Globus Medical from $28.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, October 19th. Zacks Investment Research downgraded Globus Medical from a “hold” rating to a “sell” rating in a research note on Monday, September 4th. ValuEngine downgraded Globus Medical from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Globus Medical in a research note on Thursday, October 19th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $36.83.

Shares of Globus Medical Inc (NYSE:GMED) traded down $0.10 during midday trading on Wednesday, reaching $38.43. 427,000 shares of the company’s stock were exchanged, compared to its average volume of 687,861. Globus Medical Inc has a 1 year low of $23.44 and a 1 year high of $41.70. The company has a market capitalization of $3,713.37, a PE ratio of 30.82, a P/E/G ratio of 2.92 and a beta of 0.58.

Globus Medical (NYSE:GMED) last issued its earnings results on Wednesday, November 8th. The medical device company reported $0.30 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.30. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The firm had revenue of $151.74 million for the quarter, compared to analysts’ expectations of $150.73 million. During the same quarter last year, the company posted $0.29 earnings per share. Globus Medical’s revenue was up 11.9% on a year-over-year basis. analysts forecast that Globus Medical Inc will post 1.27 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thelincolnianonline.com/2017/12/13/globus-medical-inc-gmed-holdings-decreased-by-oxford-asset-management-llp.html.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply